title: Imaging EGFR and HER2 by PET and SPECT: a review.
abstract: In an effort to discover a noninvasive method for predicting which cancer patients will benefit from therapy targeting the EGFR and HER2 proteins, a large body of the research has been conducted toward the development of PET and SPECT imaging agents, which selectively target these receptors. We provide a general overview of the advances made toward imaging EGFR and HER2, detailing the investigation of PET and SPECT imaging agents ranging in size from small molecules to monoclonal antibodies.
authors.affiliation: Department of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts.
authors.forename: Emily B
authors.initials: EB
authors.lastname: Corcoran
authors.forename: Robert N
authors.initials: RN
authors.lastname: Hanson
mesh_terms: D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D049268:Positron-Emission Tomography; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D019275:Radiopharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D066246:ErbB Receptors; D047428:Protein Kinase Inhibitors; D019275:Radiopharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases
keywords: EGFR; HER2; PET; SPECT